• Users Online: 159
  • Print this page
  • Email this page
DRUG REVIEW
Year : 2020  |  Volume : 3  |  Issue : 4  |  Page : 767-784

Ibrutinib: A narrative drug review


1 Department of Medical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, Maharashtra, India
2 Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

Correspondence Address:
Bhausaheb P Bagal
Department of Medical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Parel, Mumbai - 400 012, Maharashtra
India
Nikita Mehra
Department of Medical Oncology, Cancer Institute (WIA), Chennai - 600 036, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_234_20

Get Permissions

Ibrutinib is an oral, irreversible covalent inhibitor of the Bruton tyrosine kinase, that plays a major role in B-cell differentiation, proliferation, migration, survival, and apoptosis. It has been found to be active against a number of B-cell malignancies. Ibrutinib has shifted the treatment strategy for malignancies away from cytotoxic chemotherapies toward a more targeted approach. It has already been approved for a number of B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, and chronic graft-versus-host disease in allogeneic stem cell transplant recipients, and still continues to be evaluated for a number of other B-cell malignancies in various settings. We comprehensively searched the PubMed database to identify and compile the current scenarios in which ibrutinib is indicated for use in oncological practice.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed437    
    Printed10    
    Emailed0    
    PDF Downloaded33    
    Comments [Add]    

Recommend this journal